Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This book discusses current research on polycystic ovary syndrome, including diagnosis, management, and the impact of lifestyle changes, without reporting new clinical results.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

This review examines the use of natural remedies, including various herbs, for treating polycystic ovary syndrome, but reports no new clinical results.

This study highlights that polycystic ovary syndrome develops through genetic and environmental factors, with insulin resistance as a key mechanism, impacting the risk of metabolic and cardiovascular conditions.

This case report is the first to document the coexistence of bullous pemphigoid, malignant tumors, and alopecia areata in a patient, highlighting the complete resolution of skin lesions with dupilumab and spontaneous hair regrowth without disease-specific treatment.

In this study, researchers developed a reliable HPLC method to simultaneously estimate Finasteride and Tadalafil in marketed formulations, showing precise, linear results with confirmed degradation susceptibility under certain stress conditions.

In this case report, a 47-year-old man experienced systemic hair loss after starting hemodialysis, which resolved after discontinuing the antipruritic drug nalfurafine, suggesting its role in causing hair follicle capillary regression.

This study identified female sex and specific radiological findings as risk factors for chronic post-COVID syndrome, while long-term use of angiotensin-2 receptor blockers was linked to fewer chronic symptoms.

This review investigates molecular mechanisms behind PCOS pathogenesis and discusses potential therapies, but reports no new clinical results.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

This report details the experiences gained during a pharmacy internship in both hospital and community settings, highlighting the preparation of sildenafil suspensions for hospital use, patient consultations on autoimmune conditions, and educational material creation in community pharmacy, alongside insights into diabetes and ADHD treatments.

This narrative review discusses the mixed and evolving evidence regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their influence on erectile dysfunction in men with type 2 diabetes and obesity, highlighting potential benefits and concerns yet to be clarified.

In this study, mild adverse reactions to COVID-19 vaccines were reported among vaccinated staff and students, with females experiencing more reactions than males.

This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

This study found that adding pioglitazone to either spironolactone or metformin improved metabolic parameters and insulin resistance in women with PCOS, despite an increase in BMI.

This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.

This review highlights concerns about dermatological side effects linked to rapid weight loss from glucagon-like peptide-1 receptor agonists used for type 2 diabetes and obesity treatment, such as skin laxity, decreased collagen, and hair loss, emphasizing the importance of managing these while retaining metabolic benefits.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This study explores potential strategies for targeted drug delivery specifically to pancreatic beta-cells in type 2 diabetes treatment, highlighting methods for inducing drug expression in beta-cells, suitable drug carriers, active targeting peptides, and optimal administration routes.

This case presentation reported worsening hyperglycemia in a diabetic male patient after starting finasteride, suggesting that 5-alpha reductase inhibitors may induce hyperglycemia through insulin resistance and liver disturbances in some individuals.

This review indicates that glucagon-like peptide-1 receptor agonists may be linked to hair loss, raising safety concerns despite the lack of definitive causal evidence.

In this case report, a 60-year-old woman with alopecia areata and type 1 diabetes experienced hypoglycemic seizures after starting baricitinib, though reducing the dose alleviated these episodes; the study highlights the need for caution and glucose monitoring when using JAK inhibitors in at-risk patients.

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

This study reviews the role of semaglutide in obesity management, emphasizing its substantial weight-loss and metabolic benefits in diverse patients, with a focus on its mechanisms, dosing, efficacy, and safety.

This study found that linc-PINT expression was significantly decreased in patients with atrial fibrillation compared to healthy controls, while several TGF-β signaling genes were increased, suggesting a potential role in heart arrhythmias' pathogenesis.

In this study, researchers found that metformin improved glycaemic control and other metabolic parameters in non-diabetic patients on glucocorticoid treatment, also reducing pneumonia risk and hospital admissions, suggesting a potential advantage for routine use in this population.

This review examines how GLP-1 receptor agonists might impact metabolic and reproductive outcomes in polycystic ovary syndrome, but it reports no new clinical findings and highlights the need for further research.